NCT03379844已完成2 期
Holmium-166-radioembolization in Patients With Unresectable Hepatocellular Carcinoma (HCC); a Multi-center, Interventional, Non-randomized, Non-comparative, Open Label, Early Phase II Study: HEPAR Primary
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- UMC Utrecht
- 入组人数
- 30
- 试验地点
- 4
- 主要终点
- Safety, expressed as the rate of unacceptable toxicity.
研究概览
简要总结
Patients with hepatocellular carcinoma often die from intrahepatic disease since current treatment options are generally limited. Local treatment using holmium radioembolization could offer an effective treatment and a more personal approach than yttrium radioembolization (standard-of-care) as holmium has more imaging options.
详细描述
Primary objective:
• To establish the safety and toxicity profile of holmium radioembolization in patients with hepatocellular carcinoma.
Secondary objectives:
- To evaluate efficacy of holmium radioembolization in hepatocellular carcinoma without curative treatment options in a non-comparative phase II study.
- To evaluate tumor marker response.
- To evaluate Quality of Life (QoL).
- To evaluate biodistribution / dosimetry.
- To evaluate hepatic function.
Study design: Multi-center, interventional, treatment, non-randomized, open label, non-comparative, early phase II study. The study is a collaboration between UMC Utrecht and Erasmus MC Rotterdam. Recruitment and treatment of patients will take place in both centers.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have given written informed consent.
- •Female or male aged 18 years and over.
- •Diagnosis of HCC established according to the Netherlands HCC guideline criteria (in line with American AASLD criteria): nodule >1 cm in a patient at risk for HCC, with combination of arterial hypervascularity and venous or delayed phase wash-out on multiphase CT-scan or MRI-scan.2, 4 LR-5 and LR- 4 based on Liver Imaging Reporting and Data System can be included based on discretion of the principal investigator.I
- •No curative treatment options (resection, transplant, or in case of solitary tumor <5 cm, RFA).
- •Life expectancy of at least 6 months.
- •ECOG Performance status 0-1 (Table 2).
- •Liver-dominant disease (maximum 5 lung nodules all ≤1.0 cm and mesenteric or portal lymph nodes all ≤2.0 cm are accepted).
- •Child-Pugh class A5-6 or B
- •At least one measurable liver lesion according to the modified RECIST criteria.21
- •Negative pregnancy test for women of childbearing potential. Female patients of child-bearing potential should use an highly effective acceptable method of contraception (oral contraceptives, barrier methods, approved contraceptive implant, long-term injectable contraception, intrauterine device or tubal ligation) or should be more than 1 year postmenopausal or surgically sterile during their participation in this study (from the time they sign the consent form), to prevent pregnancy.
排除标准
- •Evidence of significant extrahepatic disease (MRI-scan liver and multiphase abdominal CT as well as a thoracic CT are routinely performed at screening).
- •Radiation therapy within the last 4 weeks before the start of study therapy.
- •Previous or current treatment with RE. Previous treatment with TACE, surgery, RFA, and previous or current treatment with sorafenib are allowed.
- •Major surgery within 4 weeks or incompletely healed surgical incision before starting study therapy.
- •Serum bilirubin >34.2 micromole/L (2 mg/dL).
- •Glomerular filtration rate <35 ml/min, determined according to the Modification of Diet in Renal Disease formula.
- •Non-correctable INR >1.5 in case of femoral approach (as opposed to radial).
- •Leukocytes <2 109/l and/or platelet count <50 109/l.
- •Significant cardiac event (e.g. myocardial infarction, superior vena cava (SVC) syndrome, New York Heart Association (NYHA) classification of heart disease ≥2 within 3 months before entry, or presence of cardiac disease that in the opinion of the Investigator increases the risk of ventricular arrhythmia.
- •Pregnancy or breastfeeding.
- •Patients suffering from psychic disorders that make a comprehensive judgment impossible, such as psychosis, hallucinations and/or depression.
- •Patients who are declared incapacitated.
- •Previous enrollment in the present study.
- •Male patients who are not surgically sterile or do not use an acceptable method of contraception during their participation in this study (from the time they sign the consent form) to prevent pregnancy in a partner.
- •Evidence of untreated, clinically significant grade 3 portal hypertension (i.e. large varices at oesophago-gastro-duodenoscopy). In these cases, therapy with non-selective beta blocker (propranolol) or rubber band ligation should be instituted according to accepted guidelines. In case of small varices, prophylactic propranolol is advised.
- •Portal vein thrombosis (tumor and/or bland) of the main branch (diagnosed on contrast enhanced transaxial images). Involvement of the right or left portal vein branches and more distal is accepted.
- •Untreated active hepatitis. In case of detectable viral HBV load, treatment with a nucleos(t)ide analog such as entecavir or tenofovir should be instituted.
- •Transjugular intrahepatic portosystemic shunt (TIPS).
- •Body weight over 150 kg (because of maximum table load).
- •Severe allergy for intravenous contrast used (Visipaque®)(because of CT evaluation, pre-treatment angiography and treatment angiography).
- •Lung shunt >30 Gy, as calculated using scout dose SPECT/CT.
- •Uncorrectable extrahepatic deposition of scout dose activity. Activity in the falciform ligament, portal lymph nodes and gallbladder is accepted.
结局指标
主要结局
Safety, expressed as the rate of unacceptable toxicity.
时间窗: Up to 6 months
Safety, expressed as the rate of unacceptable toxicity, which is the occurrence of RE-induced liver disease, defined as a total bilirubin increase grade 3 or higher according to the CTCAE version 4.03, in combination with ascites and low albumin, in the absence of disease progression
次要结局
- Tumor response based on radiologic assessment of MRI scans using mRECIST(Up to 6 months)
- Changes in tumor marker alpha-fetoprotein(Up to 6 months)
- Quality of Life (QoL) using EORTC C30(Up to 6 months)
- Quality of Life (QoL) using EORTC HCC18(Up to 6 months)
- Quality of Life (QoL) using BPI-SF(Up to 6 months)
- Biodistribution/dosimetry based on quantitative assessment of MRI scans(Up to 6 months)
- Changes in hepatic function as determined by hepatobiliary scintigraphy(Up to 3 months)
研究者
研究点 (4)
Loading locations...
相似试验
招募中
不适用
Individualized Dosimetry for Holmium-166-radioembolization in Patients With Unresectable Hepatocellular CarcinomaHepatocellular Carcinoma Non-resectableNCT05114148UMC Utrecht30
已完成
不适用
Safety and Feasibility of Radioembolization Using Ho-166 in Patients With Unresectable Hepatocellular CarcinomaHepatocellular CarcinomaNCT05643391Erasme University Hospital20
已完成
2 期
Holmium-166-radioembolization in NET After Lutetium-177-dotatate; an Efficacy StudyNeuroendocrine TumorsNCT02067988UMC Utrecht34
已完成
2 期
Adjuvant hepatic Holmium-166-radioembolization in patients with unresectable liver metastases of neuroendocrine origin, who have been treated with Lutetium-177-dotatate; a single center, interventional, non-randomized, non-comparative, open label, phase II studylever- en galwegneoplasmata malgine en niet-gespecificeerdliver metastases of neuroendocrine tumor1001981510014713NL-OMON45045niversitair Medisch Centrum Utrecht48
已完成
不适用
Holmium Radioembolization as Adjuvant Treatment to RFA for Early Stage HCC: Dose Finding StudyEarly Stage HCCHCCNCT03437382Leiden University Medical Center20